The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or “the Company”) (NYSE: TFX) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Teleflex is the subject of an article published by Fierce Biotech on February 27, 2025, titled: “Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.” According to the article, the Company “has announced a plan to split its business into two separate independent companies—and it’s setting up one of its future scions with a new portfolio of cardiovascular device assets, set to be acquired from Biotronik.” Based on this news, shares of Teleflex fell by 21.6% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250430335372/en/